Popular on EntSun
- EchoDreams Production to Unveil Latest Film and Videos - 104
- Introducing Luxevibe.io: The Trendsetting Hub for Luxe Beauty Reviews and Lifestyle Inspiration - 102
- Experience Handcrafted Elegance With Handbag Designer, Treniece Green This Upcoming BVFW x NYFW 24
- David Rice aka DJ Spin$ of Flint, MI, Achieves MRAA Palladium Certification for "Tank Moves"
- Jazz Fusion Drummer Bob Holz To Play Syracuse, NY
- Tia P. Releases Empowering Anthem "Kamala Who?" Celebrating Kamala Harris as the Democratic Presidential Nominee
- Montice Harmon Celebrates "Eclipse" with New Remix
- The Leading Private Autopsy Company Now Offering Services in All 50 States
- Gucci's Changemaker Recipient, Anya Dillard Joins BVFW x NYFW 24'
- Chris Funk (The Wonderist) Brings Magic to Life at The Phantom Projects Theatre at La Habra Depot
Similar on EntSun
- The Ripple Effect Arts, has launched its latest product, Organic Wild Yam Cream, capitalizing on the company's recent viral success on TikTok
- NRx Pharmaceuticals NRXP: Prominently Featured in Psychiatrist.com; Article Titled "How NRx Could Upend the Fight Against Depression and Suicide"
- CCHR Seeks Redress for Those Forcibly Held and Harmed in Behavioral Facilities
- DocVilla Introduces Best All-in-One Customizable Cloud-Based EHR Practice Management Software for Multi-Specialty and Small Practices
- Sycamore Hills Dentistry Welcomes the Yomi Robot: The Future of Dental Implant Surgery
- Cooking with Claudine Re-Launches in September with Fresh, Organic, and Gluten-Free Meal Delivery in the San Francisco Bay Area
- Dr. Seth Chambers Shares Journey to Success in Implant Dentistry on Unofficial Podcast's Summer Series: "Mind, Body, & Arches"
- Health is for EveryBODY™ Campaign Partners with Chip In™
- Melanated Cares Foundation to Host 2024 Annual Camping Retreat "Melanated Campout" Powered by Winnebago Industries Foundation
- Health is for EveryBODY™ Welcomes Ciba Health as a Sponsor
YouthBio Therapeutics Announces Significant Results from Joint Study with Dr. Ocampo Demonstrating Amelioration of Age-Related Cognitive Decline
EntSun News/11032921
SEATTLE - EntSun -- YouthBio Therapeutics (YouthBio), a pioneering longevity biotechnology company developing partial reprogramming-based gene therapies, today announced significant research results from its collaboration with Dr. Alejandro Ocampo, Professor at the University of Lausanne and a leading figure in aging research whose pioneering work has given rise to the partial reprogramming field.
The study, titled "Neuron-specific partial reprogramming in the dentate gyrus impacts mouse behavior and ameliorates age-related decline in memory and learning," demonstrates that brain-specific induction of partial reprogramming can ameliorate cognitive decline associated with aging. These findings add to the growing body of evidence for the therapeutic potential of in vivo partial reprogramming for the prevention and treatment of neurodegenerative disorders.
Key Findings
This study used two different approaches: a neuron-specific transgenic reprogrammable mouse model and a neuron-specific targeted lentiviral delivery of OSKM reprogramming factors. Both methods showed that partial reprogramming of adult neurons in the dentate gyrus of the hippocampus impacts animal behavior and cognitive function, and mitigates age-related decline in memory and learning.
"These exciting findings from our collaboration with Dr. Ocampo validate our approach and highlight the transformative potential of partial reprogramming in combating age-related cognitive decline," said Yuri Deigin, CEO and co-founder of YouthBio. "We are thrilled to see such promising results and are committed to advancing this research further."
Dr. Ocampo added, "I am delighted to collaborate with YouthBio to accelerate clinical translation of partial cellular reprogramming for treating age-related diseases, particularly neurodegenerative conditions. It is also very exciting to see other research groups demonstrating lifespan extension in wildtype mice through partial reprogramming. I believe that once we fully understand how to use this approach in a tissue-specific manner – something that YouthBio has recognized since the company's inception – we will see even greater increases in lifespan and more beneficial therapeutic effects in various disease models."
More on EntSun News
"The potential of partial reprogramming for brain rejuvenation and the treatment of neurodegenerative disorders is very promising," said João Pedro de Magalhães, Ph.D., Chief Scientific Officer of YouthBio. "Our recent findings suggest that partial reprogramming could play a significant role in addressing age-related cognitive decline. While there is still much to learn and refine, these early results are encouraging and provide a solid foundation for further research. We are cautiously optimistic that with continued investigation, we can develop effective therapies that may one day benefit patients suffering from conditions like Alzheimer's disease."
Future Plans and Alzheimer's Research
YouthBio is committed to investigating the use of partial reprogramming in the CNS with a particular focus on Alzheimer's disease. In another study using transgenic ARTE10 mice treated with brain-specific inducible OSKM vectors, YouthBio observed reduced amyloid beta levels and a lower brain plaque burden in pivotal areas such as the hippocampus, and improved cognitive performance in behavioral tests compared to untreated controls. Based on these promising results, YouthBio has filed a provisional patent application with the USPTO.
YouthBio's results are independently validated by a team of researchers from Altos Labs, the University of Barcelona, and the Max Planck Institute, who demonstrated favorable outcomes in preventing Alzheimer's symptoms through brain-specific partial reprogramming in a 5xFAD mouse model. Their study, "Expansion of the Neocortex and Protection from Neurodegeneration by In Vivo Transient Reprogramming," corroborates YouthBio's positive findings.
"Our positive Alzheimer's data, along with the independent positive results by Altos Labs and its collaborators, reinforces our confidence in partial reprogramming's ability to provide a novel treatment paradigm for neurodegenerative conditions," said Deigin. "Our next key milestone is to bring our Alzheimer's therapy to clinical trials, and we are fully committed to achieving this goal."
More on EntSun News
Clinical Trials and Beyond
YouthBio aims to advance its Alzheimer's disease therapy to clinical trials within three years. During this period, the company will conduct the necessary preclinical studies, GMP manufacturing, and regulatory preparations essential for filing an Investigational New Drug (IND) application with the FDA.
Concurrently, YouthBio will continue its discovery program, led by CSO Dr. João Pedro de Magalhães, to identify superior rejuvenating factors beyond the Yamanaka factors for use in subsequent generations of its tissue-specific gene therapies. The company will also conduct several proof-of-concept animal studies in other CNS indications and continue its progeria program.
In their progeria program, YouthBio was granted a Rare Pediatric Disease Designation by the FDA for YB-001 for the treatment of Hutchinson-Gilford progeria syndrome (HGPS). This designation makes YouthBio eligible to receive a Priority Review Voucher (PRV) if YB-001 is approved for treating progeria. The PRV can be redeemed for an expedited priority review of any subsequent marketing application or it can be sold. Historical PRV transaction values have exceeded $100mm, reaching as high as $350mm.
***
About YouthBio Therapeutics, Inc.
YouthBio Therapeutics (https://youthbiotx.com) is a longevity company developing gene therapies that leverage partial reprogramming to restore a more youthful gene expression profile in targeted cells, leading to positive therapeutic effects in corresponding organs. It is currently focused on brain-specific gene therapies targeting CNS diseases, with Alzheimer's disease being the primary program.
The study, titled "Neuron-specific partial reprogramming in the dentate gyrus impacts mouse behavior and ameliorates age-related decline in memory and learning," demonstrates that brain-specific induction of partial reprogramming can ameliorate cognitive decline associated with aging. These findings add to the growing body of evidence for the therapeutic potential of in vivo partial reprogramming for the prevention and treatment of neurodegenerative disorders.
Key Findings
This study used two different approaches: a neuron-specific transgenic reprogrammable mouse model and a neuron-specific targeted lentiviral delivery of OSKM reprogramming factors. Both methods showed that partial reprogramming of adult neurons in the dentate gyrus of the hippocampus impacts animal behavior and cognitive function, and mitigates age-related decline in memory and learning.
"These exciting findings from our collaboration with Dr. Ocampo validate our approach and highlight the transformative potential of partial reprogramming in combating age-related cognitive decline," said Yuri Deigin, CEO and co-founder of YouthBio. "We are thrilled to see such promising results and are committed to advancing this research further."
Dr. Ocampo added, "I am delighted to collaborate with YouthBio to accelerate clinical translation of partial cellular reprogramming for treating age-related diseases, particularly neurodegenerative conditions. It is also very exciting to see other research groups demonstrating lifespan extension in wildtype mice through partial reprogramming. I believe that once we fully understand how to use this approach in a tissue-specific manner – something that YouthBio has recognized since the company's inception – we will see even greater increases in lifespan and more beneficial therapeutic effects in various disease models."
More on EntSun News
- Always The VIP Launches Promotional Dinner Parties at Fushimi in Times Square NYC
- Green Office Partner Ranked #1 on Crain's 2024 List of Best Places to Work in Chicago
- Winnie Stackz Presents Couture Fighting Cancer Part 3 In Atlanta, Ga
- Diversified Industrial Acquisition Agreement, Plus Major Contract Award for Large Fleet Trucking Provider: MingZhu Logistics: Stock Symbol: YGMZ
- Messageware Z-Day Guard v1.5 Expands MDR Security to Azure, Exchange, and Windows Servers
"The potential of partial reprogramming for brain rejuvenation and the treatment of neurodegenerative disorders is very promising," said João Pedro de Magalhães, Ph.D., Chief Scientific Officer of YouthBio. "Our recent findings suggest that partial reprogramming could play a significant role in addressing age-related cognitive decline. While there is still much to learn and refine, these early results are encouraging and provide a solid foundation for further research. We are cautiously optimistic that with continued investigation, we can develop effective therapies that may one day benefit patients suffering from conditions like Alzheimer's disease."
Future Plans and Alzheimer's Research
YouthBio is committed to investigating the use of partial reprogramming in the CNS with a particular focus on Alzheimer's disease. In another study using transgenic ARTE10 mice treated with brain-specific inducible OSKM vectors, YouthBio observed reduced amyloid beta levels and a lower brain plaque burden in pivotal areas such as the hippocampus, and improved cognitive performance in behavioral tests compared to untreated controls. Based on these promising results, YouthBio has filed a provisional patent application with the USPTO.
YouthBio's results are independently validated by a team of researchers from Altos Labs, the University of Barcelona, and the Max Planck Institute, who demonstrated favorable outcomes in preventing Alzheimer's symptoms through brain-specific partial reprogramming in a 5xFAD mouse model. Their study, "Expansion of the Neocortex and Protection from Neurodegeneration by In Vivo Transient Reprogramming," corroborates YouthBio's positive findings.
"Our positive Alzheimer's data, along with the independent positive results by Altos Labs and its collaborators, reinforces our confidence in partial reprogramming's ability to provide a novel treatment paradigm for neurodegenerative conditions," said Deigin. "Our next key milestone is to bring our Alzheimer's therapy to clinical trials, and we are fully committed to achieving this goal."
More on EntSun News
- Oh Polly takes on New York Fashion Week with Fashion PR Firm covering the event
- HOW WE FEEL Announces Debut Single "Make It Out Alive" Premiering on September 27
- De'Garryan Andrews Takes Center Stage in Anthony Lamarr White's "Hour of the Wolf"
- Horror Short BABUSHKA From Thorny Devil Productions and Five-Tool Player Embark On Festival Journey
- The Ripple Effect Arts, has launched its latest product, Organic Wild Yam Cream, capitalizing on the company's recent viral success on TikTok
Clinical Trials and Beyond
YouthBio aims to advance its Alzheimer's disease therapy to clinical trials within three years. During this period, the company will conduct the necessary preclinical studies, GMP manufacturing, and regulatory preparations essential for filing an Investigational New Drug (IND) application with the FDA.
Concurrently, YouthBio will continue its discovery program, led by CSO Dr. João Pedro de Magalhães, to identify superior rejuvenating factors beyond the Yamanaka factors for use in subsequent generations of its tissue-specific gene therapies. The company will also conduct several proof-of-concept animal studies in other CNS indications and continue its progeria program.
In their progeria program, YouthBio was granted a Rare Pediatric Disease Designation by the FDA for YB-001 for the treatment of Hutchinson-Gilford progeria syndrome (HGPS). This designation makes YouthBio eligible to receive a Priority Review Voucher (PRV) if YB-001 is approved for treating progeria. The PRV can be redeemed for an expedited priority review of any subsequent marketing application or it can be sold. Historical PRV transaction values have exceeded $100mm, reaching as high as $350mm.
***
About YouthBio Therapeutics, Inc.
YouthBio Therapeutics (https://youthbiotx.com) is a longevity company developing gene therapies that leverage partial reprogramming to restore a more youthful gene expression profile in targeted cells, leading to positive therapeutic effects in corresponding organs. It is currently focused on brain-specific gene therapies targeting CNS diseases, with Alzheimer's disease being the primary program.
Source: YouthBio Therapeutics
0 Comments
Latest on EntSun News
- Dezerland Park to host GEM Wedding Expo
- Phinge's Plan to Save Free Speech and Give Everyone the Right to Personal Privacy and Ownership and Monetization of Their Online Data and Content
- The Royalty Network and CEO Frank Liwall Appoint Daniel Abowd as New President & General Counsel
- African-American Marketing Association Launches Business of Marketing Bootcamp™ for Small Businesses
- L2 Aviation Announces Strategic Growth Investment from Argentum
- WOHLER Announces its NEW iAM1-MIX8 Next Generation MIX Series Solution @ IBC 2024
- The World's No.1 Superstar Dies After Choking on a French Fry
- Announcing the Formation of Marvis LLC and the Launch of Two New Websites
- Award-winning and Renowned Voice Actor Nancy Cartwright to Deliver Keynote at the That's Voiceover Career Expo 2024 in Los Angeles
- "Army of Liars" Exposes How Social Media Profits from Disinformation
- Vantiva Demonstrates its Vision of the Connected Home of the Future with New Lineup of AI-Powered CPE at IBC 2024
- Fashionlevel 8 Virtual Fashion Show Generate Over $1.9 Billion In Global Sales, Within 4-Hours
- EFC Sweeps Canadian Cinematography Awards With Four Award Wins
- All the way from ARUBA Ray Donato is releasing his NEW single "I'm not lonely" through label Rock Solid Talent Entertainment and it will be distrib
- Challenge Arcade's World Record Weekend 2024
- Empowering Educators with AI: Goosechase and DIGITAL Partner for the Future of Interactive Experiences
- Join Us at the 136th Canton Fair from October 15th to 19th, 2024!
- Legendary Aviation Coffee Company Celebrates 2100% Growth with Exceptional Single-Origin Air-Roasted Coffee
- General Vincent Brooks (RET) Joins BEYA Stars and Stripes Committee as a Founder, Following 20 Years of Service by General Johnnie Wilson (RET)
- SafeTea Launches App to Safeguard Women